Nanostructured lipid–carrageenan hybrid carriers (NLCCs) for controlled delivery of mitoxantrone hydrochloride to enhance anticancer activity bypassing the BCRP-mediated efflux

References

• DeMario MD, Ratain MJ. Oral chemotherapy: rationale and future directions. J Clin Oncol 1998;16:2557–67.
   PubMed Web of Science ®Google Scholar
• Bromberg L. Polymeric micelles in oral chemotherapy. J Control Release 2008;128:99–112.
   PubMed Web of Science ®Google Scholar
• Ling G, Zhang P, Zhang W, et al. Development of novel self-assembled DS-PLGA hybrid nanoparticles for improving oral bioavailability of vincristine sulfate by P-gp inhibition. J Control Release 2010;148:241–8.
   PubMed Web of Science ®Google Scholar
• Luo C, Sun J, Du Y, et al. Emerging integrated nanohybrid drug delivery systems to facilitate the intravenous-to-oral switch in cancer chemotherapy. J Control Release 2014;176:94–103.
   PubMed Web of Science ®Google Scholar
• Doughty JC, Kane E, Cooke TG, et al. Mitoxantrone and methotrexate chemotherapy with and without mitomycin C in the regional treatment of locally advanced breast cancer. Breast 2002;11:97–9.
   PubMed Web of Science ®Google Scholar
• Khalaf A, Pfister C, Hellot MF, et al. Value of mitoxantrone in metastatic hormone-resistant prostate cancer. Prog Urol 2002;12:37–42.
   PubMed Web of Science ®Google Scholar
• Hagemeister F, Cabanillas F, Coleman M, et al. The role of mitoxantrone in the treatment of indolent lymphomas. Oncologist 2005;10:150–9.
   PubMed Web of Science ®Google Scholar
• Novoselac AV, Reddy S, Sanmugarajah J. Acute promyelocytic leukemia in a patient with multiple sclerosis following treatment with mitoxantrone. Leukemia 2004;18:1561–2.
   PubMed Web of Science ®Google Scholar
• Doyle LA, Yang W, Abruzzo LV, et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 1998;95:15665–70.
   PubMed Web of Science ®Google Scholar
• Maliepaard M, van Gastelen MA, de Jong LA, et al. Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Cancer Res 1999;59:4559–63.
   PubMed Web of Science ®Google Scholar
• Müller RH, Radtke M, Wissing SA. Nanostructured lipid matrices for improved microencapsulation of drugs. Int J Pharm 2002; 242:121–8.
   PubMed Web of Science ®Google Scholar
• Ricci M, Puglia C, Bonina F, et al. Evaluation of indomethacin percutaneous absorption from nanostructured lipid carriers (NLC): in vitro and in vivo studies. J Pharm Sci 2005;94:1149–59.
   PubMed Web of Science ®Google Scholar
• Yuan H, Wang LL, Du YZ, et al. Preparation and characteristics of nanostructured lipid carriers for control-releasing progesterone by melt-emulsification. Colloids Surf B Biointerfaces 2007; 60:174–9.
   PubMed Web of Science ®Google Scholar
• Wong HL, Bendayan R, Rauth AM, et al. Development of solid lipid nanoparticles containing ionically complexed chemotherapeutic drugs and chemosensitizers. J Pharm Sci 2004;93: 1993–2008.
   Google Scholar
• Fundarò A, Cavalli R, Bargoni A, et al. Nonstealth and stealth solid lipid nanoparticles (SLN) carrying doxorubicin: pharmacokinetics and tissue distribution after i.v. administration to rats. Pharmacol Res 2000;42:337–43.
   PubMed Web of Science ®Google Scholar
• Serpe L, Satalano MG, Cavalli R, et al. Cytotoxicity of anticancer drugs incorporated in solid lipid nanoparticles on HT-29 colorectal cancer cell line. Eur J Pharm Biopharm 2004;58: 673–80.
   PubMed Web of Science ®Google Scholar
• Mussi SV, Silva RC, Oliveira MC, et al. New approach to improve encapsulation and antitumor activity of doxorubicin loaded in solid lipid nanoparticles. Eur J Pharm Sci. 2013;48:282–90.
   PubMed Web of Science ®Google Scholar
• Mussi SV, Sawant R, Perche F, et al. Novel nanostructured lipid carrier co-loaded with doxorubicin and docosahexaenoic acid demonstrates enhanced in vitro activity and overcomes drug resistance in MCF-7/Adr cells. Pharm Res 2014;31: 1882–92.
   PubMed Web of Science ®Google Scholar
• Zhang P, Ling G, Pan X, et al. Novel nanostructured lipid-dextran sulfate hybrid carriers (NLDCs) overcome tumor multidrug resistance of mitoxantrone hydrochloride. Nanomedicine 2012;8:185–93.
   PubMed Web of Science ®Google Scholar
• Jones F, Colfen H, Antonietti M. Interaction of kappa-carrageenan with nickel, cobalt, and iron hydroxides. Biomacromolecules 2000;1:556–63.
   PubMed Web of Science ®Google Scholar
• Grenha A, Gomes ME, Rodrigues M, et al. Reis development of new chitosan/carrageenan nanoparticles for drug delivery applications. J Biomed Mater Res 2010;92:1265–72. A
   Google Scholar
• Picker KM. Matrix tablets of carrageenans. I. A compaction study. Drug Dev Ind Pharm 1999;25:329–37.
   PubMed Web of Science ®Google Scholar
• Picker KM. Matrix tablets of carrageenans. II. Release behavior and effect of added cations. Drug Dev Ind Pharm 1999;25: 339–46.
   PubMed Web of Science ®Google Scholar
• Yuan HM, Song JM, Li XG, et al. Immunomodulation and antitumor activity of kappa-carrageenan oligosaccharides. Cancer Lett 2006;243:228–34.
   PubMed Web of Science ®Google Scholar
• Zhang P, Ling G, Sun J, et al. Determination of mitoxantrone in rat plasma by liquid chromatography-tandem mass spectrometry method: application to a pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci 2010;878: 2260–5.
   PubMed Web of Science ®Google Scholar
• Li Y, Wong HL, Shuhendler AJ, et al. Molecular interactions, internal structure and drug release kinetics of rationally developed polymer-lipid hybrid nanoparticles. J Control Release 2008;128:60–70.
   PubMed Web of Science ®Google Scholar
• Wong HL, Rauth AM, Bendayan R, et al. A new polymer–lipid hybrid nanoparticle system increases cytotoxicity of doxorubicin against multidrug-resistant human breast cancer cells. Pharm Res 2006;23:1574–85.
   PubMed Web of Science ®Google Scholar
• Wong HL, Bendayan R, Rauth AM, et al. Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer. J Control Release 2006;116: 275–84.
   PubMed Web of Science ®Google Scholar
• Yuan X, Shah BA, Kotadia NK, et al. The development and mechanism studies of cationic chitosan-modified biodegradable PLGA nanoparticles for efficient siRNA drug delivery. Pharm Res 2010;27:1285–95.
   PubMed Web of Science ®Google Scholar
• Paillard A, Passirani C, Saulnier P, et al. Positively-charged, porous, polysaccharide nanoparticles loaded with anionic molecules behave as ‘stealth’ cationic nanocarriers. Pharm Res 2010;27:126–33.
   PubMed Web of Science ®Google Scholar
• Wang Y, Wang R, Lu X, et al. Pegylated phospholipids-based self-assembly with water-soluble drugs. Pharm Res 2010;27: 361–70.
   PubMed Web of Science ®Google Scholar
• Zhang P, Ling G, Sun J, et al. Multifunctional nanoassemblies for vincristine sulfate delivery to overcome multidrug resistance by escaping P-glycoprotein mediated efflux. Biomaterials 2011;32: 5524–33.
   PubMed Web of Science ®Google Scholar
• Selvakumaran S, Muhamad II, Abd Razak SI. Evaluation of kappa carrageenan as potential carrier for floating drug delivery system: effect of pore forming agents. Carbohydr Polym 2016; 135:207–14.
   PubMed Web of Science ®Google Scholar
• Trédan O, Galmarini CM, Patel K, et al. Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst 2007;99: 1441–54.
   PubMed Web of Science ®Google Scholar
• Miglietta A, Cavalli R, Bocca C, et al. Cellular uptake and cytotoxicity of solid lipid nanospheres (SLN) incorporating doxorubicin or paclitaxel. Int J Pharm 2000;210:61–7.
   PubMed Web of Science ®Google Scholar
• Tang B, Fang GH, Gao Y, et al. Lipid-albumin nanoassemblies co-loaded with borneol and paclitaxel for intracellular drug delivery to C6 glioma cells with P-gp inhibition and its tumor targeting. Asian J Pharm Sci 2015;10:363–71.
   Web of Science ®Google Scholar
• Minko T, Batrakova EV, Li S, et al. Pluronic block copolymers alter apoptotic signal transduction of doxorubicin in drug-resistant cancer cells. J Control Release 2005;105:269–78.
   PubMed Web of Science ®Google Scholar
• Wong HL, Bendayan R, Rauth AM, et al. A mechanistic study of enhanced doxorubicin uptake and retention in multidrug resistant breast cancer cells using a polymer-lipid hybrid nanoparticle system. J Pharmacol Exp Ther 2006;317: 1372–81.
   PubMed Web of Science ®Google Scholar
• Roma MI, Hocht C, Chiappetta DA, et al. Tetronic® 904-containing polymeric micelles overcome the overexpression of ABCG2 in the blood-brain barrier of rats and boost the penetration of the antiretroviral efavirenz into the CNS. Nanomedicine (Lond) 2015;10:2325–37.
   PubMed Web of Science ®Google Scholar
• Singh MS, Juvale K, Wiese M, et al. Evaluation of dual P-gp-BCRP inhibitors as nanoparticle formulation. Eur J Pharm Sci 2015; 77:1–8.
   PubMed Web of Science ®Google Scholar